Chronic heart failure
349 results
201 - 300
Dapagliflozin reduces mortality and renal replacement in patients with chronic kidney disease
Vitamin D for the management of chronic obstructive pulmonary disease
Preoperative assessment - Treatment with SGLT2 inhibitors rarely results in diabetic ketoacidosis
- Amyloidosis
- Leg oedema
- Pregabalin for decreasing pancreatic pain in chronic pancreatitis: Cochrane systematic review
- ACC/AHA guidelines for the diagnosis and management of atrial fibrillation
- Mitral regurgitation
- Hydralazine in infants with persistent hypoxemic respiratory failure: Cochrane systematic review
- More evidence against antibiotics for acute asthma exacerbations
- For severe hypoxemia due to chronic obstructive pulmonary disease or pulmonary fibrosis, 24 hours of oxygen is no better than 15 hours
- SGLT-2 inhibitors in type 2 diabetes
- Methods of vascular occlusion for elective liver resections
- Prehospital emergency care
- Early treatment with ACE inhibitors in acute myocardial infarction
- Trypanosomiases
- For patients with chronic kidney disease, prehydration prior to contrast-enhanced computed tomography is unnecessary
- Cardioselective beta‐blockers for reversible airway disease
- Isolated diastolic hypertension not associated with increased risk of CVD
- Safe use of non-steroidal anti-inflammatory drugs (NSAIDs)
- Higher hemoglobin target with epoeitin alfa is harmful in CKD (CHOIR)
- No benefit to addition of stenting for treatment of atherosclerotic renal artery stenosis
- Eosinophilic pneumonia
- Diabetic kidney disease (diabetic nephropathy)
- JNC 8 report on prevention/evaluation/treatment of hypertension
- Recurrent infections and immunodeficiencies in children
- Riociguat for pulmonary hypertension
- ACC/AHA guideline for the management of patients with chronic coronary disease
- Prolonged cough in adults
- Chronic coronary syndrome (coronary heart disease)
- Antioxidants for adults with chronic kidney disease
- Respiratory failure
- Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia
- Systemic lupus erythematosus (SLE)
- Hypertension: investigations, treatment initiation and non-pharmacological treatment
- Glucagon‐like peptide 1 (GLP‐1) receptor agonists for people with chronic kidney disease and diabetes
- Adults with varicose veins are at increased risk of DVT
- In adults with medical comorbidities, influenza vaccinations are associated with a lower risk of developing dementia
- Short-term high-flow oxygen therapy for low-risk patients decreases reintubation rates
- Cinnamon for diabetes mellitus
- Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease
- Rosuvastatin does not improve outcomes in HF with average lipids
- Interleukin‐receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases
- SGLT2 inhibitors, GLP1 agonists provide greater benefit for patients with type 2 diabetes
- Haemoptysis
- Eplerenone for hypertension
- Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
- Assessment of ventricular hypertrophies from an ECG
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- Treatment of chronic renal failure
- Insomnia
- Lower costs and healthcare utilization with hospital care at home
- Sotrovimab reduces the likelihood of hospitalization in at-risk outpatients with mild to moderate COVID-19 (NNT = 16)
- Higher risk of bleeding events associated with concomitant use of amiodarone and direct oral anticoagulants
- Immunosuppressive T‐cell antibody induction for heart transplant recipients
- Interactive telemedicine: effects on professional practice and health care outcomes
- Altered dietary salt intake for preventing diabetic kidney disease and its progression
- Oral antidiabetic drugs and GLP-1 analogues
- Ipratropium associated with increase risk of CV events
- No decrease in all-cause mortality with LMWH for VTE prophylaxis in hospitalized medical patients
- Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases: Cochrane systematic review
- Blood pressure targets in adults with hypertension
- SGLT2 inhibitors reduce cardiovascular mortality but benefit is modest, even in patients with established heart disease (NNT = 200 for 3 years)
- The most common types of acquired adult valvular heart disease and associated murmurs
- Transfusion thresholds for guiding allogeneic red blood cell transfusion
- Guidelines for obstructive sleep apnea and insomnia from the US Departments of Defense and Veteran Affairs
- Patient navigators reduce readmission rates for high-risk older patients
- Water for preventing urinary stones
- Osteoporosis
- aDrugs commonly causing poisonings
- Antidepressants for depression in physical illness
- Colchicine reduces myocardial infarction and revascularization in patients with established coronary disease (LoDoCo2)
- Apixaban slightly more effective and safe than warfarin, but more expensive
- Secondary hypertension
- Interventions for weight loss in people with chronic kidney disease who are overweight or obese
- Effect of cyclosporine on blood pressure: Cochrane systematic review
- Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
- Phosphodiesterase 5 inhibitors for pulmonary hypertension
- High-dose influenza vaccine no more effective than the standard dose for adults with high-risk cardiovascular disease
- Two-day oral dexamethasone course effective in treatment of mild asthma exacerbation
- Wells score not helpful in hospitalized patients with suspected DVT
- Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
- Glucagon-like peptide analogues (GLP-1 analogues) for type 2 diabetes
- Acute abdomen in the adult
- Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
- Cirrhosis of the liver
- Liraglutide reduces mortality (NNT = 71) in patients with T2DM and very high CV risk
- Early referral to specialist nephrology services for preventing the progression to end‐stage kidney disease
- Polycystic kidney disease
- Aldosterone antagonists for people with chronic kidney disease requiring dialysis
- Acute coronary syndrome